The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice.
The forced swimming test (FST) is a widely used behavioural model to predict potential antidepressant (AD) action of compounds in humans. It has been previously shown that pretreatment with lithium, quinine and clonidine had additive effects on AD drugs in the FST, an effect proposed to be a result of potassium channel blockade. It is possible that pretreatment with potassium channel openers may induce opposite effects to those seen following pretreatment with potassium channel blockers in the FST. Pretreatment with cromakalim (CROM) (1 mg/kg, intraperitoneally [i.p.]) antagonized the anti-immobility effect of the mixed noradrenaline (NA)/5-hydroxytryptamine (5-HT) reuptake inhibitors imipramine and amitriptyline (P < 0.05). CROM administration (0.06 and 1 mg/kg, i.p.) also blocked the AD-like effects of the specific NA reuptake inhibitor, desipramine, and the selective serotonin reuptake inhibitor, paroxetine (P < 0.05 and P < 0.01, respectively). Pretreatment with CROM via gavage (1 mg/kg) antagonized the AD-like effects of imipramine, amitiptyline, desipramine and paroxetine. CROM treatment (via i.p. route or gavage) did not have any significant effect on the anti-immobility activity of the atypical AD mianserin at any of the doses employed. Another potassium channel opener, minoxidil (MINOX), which does not cross the blood-brain barrier, was also tested to eliminate the possibility that CROM may be acting via peripheral/local mechanisms. MINOX (32 mg/kg) failed to antagonize anti-immobility effects of any of the AD tested. In conclusion, the results of the present study suggest that CROM is only acting on drugs involved with neurotransmitter uptake inhibition.
Redrobe
J P
JP
Department of Pharmacology, GIS Medicament, Nantes cedex, France.
Pinot
P
P
Bourin
M
M
D000639:Amitriptyline / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001578:Benzopyrans / Q000494:pharmacology*; D019806:Cromakalim; D003891:Desipramine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004347:Drug Interactions; D007099:Imipramine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008124:Locomotion / Q000187:drug effects; D008297:Male; D008803:Mianserin / Q000494:pharmacology; D051379:Mice; D008914:Minoxidil / Q000494:pharmacology; D017374:Paroxetine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D005082:Physical Exertion / Q000187:drug effects*; D015221:Potassium Channels / Q000187:drug effects*; D011758:Pyrroles / Q000494:pharmacology*; D013550:Swimming
D000928:Antidepressive Agents; D001578:Benzopyrans; D015221:Potassium Channels; D011758:Pyrroles; D019806:Cromakalim; D000639:Amitriptyline; D008803:Mianserin; D017374:Paroxetine; D008914:Minoxidil; D007099:Imipramine; D003891:Desipramine